Cite

HARVARD Citation

    Vermorken, J. et al. (n.d.). P-133A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer. Annals of oncology. p. . [Online]. 
  
Back to record